SCHEMBL24036713

SCHEMBL24036713

COC(=O)C[C@H](NC(=O)CNC(=O)OC(C)(C)C)c1cc(OC(F)F)cc(OC(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.36
PTPRB P23467 1/20 0.34
MAPT P10636 2/20 0.33
HPGD P15428 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33
ITGB5 P18084 1/20 0.33
ITGB6 P18564 1/20 0.33
EPHX2 P34913 2/20 0.32
GPR139 Q6DWJ6 2/20 0.32
KDM4E B2RXH2 2/20 0.32
GAA P10253 2/20 0.32
PKM P14618 1/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31
CASP1 P29466 1/20 0.31
RAB9A P51151 1/20 0.31
CASP7 P55210 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25624528 0.93 EPAS1 (0.35) APLNRPTPRBMAPTHPGDALDH1A1
SCHEMBL24036817 0.93 ITGB3 (0.34) APLNRPTPRBMAPTHPGDALDH1A1
SCHEMBL24036816 0.92 ITGB3 (0.35) APLNRPTPRBMAPTHPGDALDH1A1
SCHEMBL24036744 0.92 ITGB3 (0.40) APLNRPTPRBITGB3ITGAVITGB5
SCHEMBL24036705 0.89 PKM (0.38) APLNRPTPRBEPHX2GPR139PKM
SCHEMBL24037076 0.85 ITGB3 (0.33) PTPRBMAPTITGB3ITGAVITGB5
SCHEMBL24036716 0.84 EGFR (0.35) APLNRPTPRBMAPTHPGDALDH1A1
SCHEMBL24036718 0.83 EGFR (0.35) APLNRPTPRBMAPTHPGDALDH1A1
SCHEMBL25624224 0.83 ITGB3 (0.39) PTPRBMAPTHPGDALDH1A1TSHR
SCHEMBL24036750 0.82 GPR139 (0.50) ITGB3ITGAVITGB5ITGB6EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE株式会社 2023-05-19 WO disclosed
WO-2021230325-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE 宇部興産株式会社 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 APLNR 3998/4885PTPRB 3627/4885MAPT 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.